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The nuclear receptor PPARα has been implicated in
lipid and glucose homeostasis, although high affinity
endogenous ligands have been elusive. The lipid
oleylethanolamide has now been shown to be a true
natural ligand for PPARα, and to participate in the
regulation of food intake and body weight.
The epidemic of obesity and its unfortunate sequelae —
including, but not limited to, type 2 diabetes, cardio-
vascular disease and certain cancers — continues to
grow. Fortunately, recent discoveries have inspired a
veritable gold rush of scientific activity on energy
balance in academic and industrial labs alike. As a con-
sequence, we have learned more about the central and
peripheral regulation of appetite, adiposity, energy
expenditure and nutrient metabolism in the last decade
than in the preceding 100 years. No area has drawn
more attention than the control of food intake, a field
that got a huge boost in 1994 with the discovery of the
adipocyte-derived hormone leptin [1]. Following that
seminal finding, a whole panoply of other endogenous
peptides have been identified that also play important
roles in regulating body weight, including the melano-
cortins, neuropeptide Y (NPY), ghrelin, melanin-con-
centrating hormone (MCH) and others [2,3].
An unusual fatty acid ethanolamide has recently been
added to the list of molecules that affect food intake.
This molecule, oleylethanolamide, has structural simi-
larity to the endogenous cannabinoid anandamide [4].
Because cannabinoids can induce hunger — as is well
known to marijuana smokers who get the ‘munchies’ —
a group of researchers decided to test whether
oleylethanolamide could also affect food intake in
rodents. Interestingly, they found that oleylethanolamide
suppresses food intake, an effect opposite to that of
anandamide [5]. Subsequent experiments showed that
oleylethanolamide does not interact with the cannabi-
noid receptor. These data indicated that fatty acid
ethanolamides have a surprising range of functions in
the control of appetite, and opened the door for the 
discovery of a new receptor involved in mediating 
this process. 
Many factors that regulate food intake, such as leptin
and ghrelin, operate by directly stimulating receptors
within the hypothalamus. These hormones interact with
receptors on specific neurons in the arcuate nucleus, a
region known to control appetite and body weight [2,3].
If small doses of leptin are injected directly into the
central nervous system, for example, the effect is iden-
tical to that observed when the protein is administered
peripherally. Other compounds affect appetite through
both central and peripheral mechanisms. Cholecys-
tokinin, for example, is a peptide secreted by the prox-
imal small intestine in response to the ingestion of food,
from whence it can act by direct stimulation of recep-
tors in either the brain or the peripheral nervous system,
specifically the vagus nerve [6]. 
If the vagus nerve is cut or damaged by a drug such
as capsaicin, cholecystokinin’s ability to reduce food
intake is reduced. Similar experiments have shown that
peripheral afferent neurons are also important for the
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Figure 1. Role of oleylethanolamide in appetite regulation.
The ingestion of food (1) stimulates oleylethanolamide produc-
tion in the proximal small intestine. Oleylethanolamide binds
and activates its receptor, PPARα, probably in the epithelium
(2), and PPARα-mediated transcriptional regulation of an as yet
unidentified target gene(s) results in activation of peripheral
afferents. These afferents terminate on appetite-regulating
neurons in the brainstem and hypothalamus (3). 
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feeding effects of oleylethanolamide, but unlike chole-
cystokinin, oleylethanolamide is completely unable to
reduce food intake when injected directly into the brain
[5]. This suggests that oleylethanolamide’s effects are
fully mediated by peripheral activation of sensory
nerves, presumably involving the vagus nerve (Figure
1). When oleylethanolamide is fed to rats, neuronal
activity — measured indirectly as elevations in c-fos
transcription — goes up in the paraventricular nucleus
of the hypothalamus and the nucleus of the solitary
tract of the brainstem, areas known to be associated
with appetite control. Furthermore, oleylethanolamide
levels have been shown to rise in the wall of the
proximal small intestine upon feeding, and to fall with
fasting [5], consistent with a role as an integrator of
nutrient metabolism and food intake.
Perhaps the most obvious remaining question about
oleylethanolamide has been the nature of its receptor.
This question has now been answered by Fu et al. [7],
who have identified the oleylethanolamide receptor as
the peroxisome proliferator-activated receptor α
(PPARα), an intriguing finding that unites two extremely
hot areas of metabolic research, the control of food
intake and the molecular biology of lipid and glucose
homeostasis. As important as this finding is for the
fields of obesity and metabolism, the therapeutic impli-
cations are likely to extend into seemingly unrelated
areas such as the prevention and treatment of cancer
and inflammatory diseases. 
The PPARs are a subgroup of the large nuclear
receptor superfamily [8]. Nuclear receptors are ligand-
gated transcription factors that transduce physiologi-
cal signals into gene expression changes in a
bewildering array of biological activities, including
organogenesis, cellular differentiation, reproduction,
growth, bone mineralization and a plethora of other
activities. The three PPAR genes in the human genome
encode three basic protein isoforms, PPARα, PPARδ
(sometimes called PPARβ) and PPARγ (Figure 2). An
enormous body of work on PPARs over the last decade
or so has revealed an extraordinary amount about their
biology, and there are important drugs on the market
specifically targeting their actions on lipid (PPARα) and
glucose levels (PPARγ).
PPARα has been implicated in variety of metabolic
processes, although notably not in the regulation of
food intake. It is expressed in a variety of tissues, but
most prominently in liver, heart, kidney, muscle and
brown adipose tissue [9]. It is involved in up-regulating
genes that affect many of the pathways operating in the
fasting state, such as gluconeogenesis, ketogenesis
and fatty acid uptake and oxidation. In concordance
with this, PPARα null mice appear normal on a chow
diet, but when fasted they become hypoglycemic,
hypertriglyceridemic and hypoketonemic, with excess
lipid stores in liver and other tissues [10,11]. Interest-
ingly, PPARα null mice exhibit a non-significant
decrease in food intake, an effect either neutral or in
opposition to that predicted by the oleylethanolamide
data [12].
Endogenous high-affinity ligands have not previously
been identified for any PPAR isoform. Despite this,
several synthetic ligands of PPARα were discovered
empirically, and have been used clinically to reduce
plasma lipid levels. These agents, collectively known
as fibrates, have been shown to reduce body weight in
obese rodent models, but until recently the effect had
not been linked to reduced food intake [12]. Fu et al. [7]
have now reported that oleylethanolamide binds to the
ligand-binding domain of PPARα with an affinity in the
mid-nanomolar range, consistent with the measured
endogenous levels of oleylethanolamide inside the
cells of the small intestine. This effect was specific for
PPARα, as PPARδ and PPARγ showed little or no
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Figure 2. The PPARs.
(A) PPARα, δ, γ1 and γ2 all have the typical
domain structure of a nuclear hormone
receptor, with a central DNA-binding
domain (DBD) and a carboxy-terminal
ligand-binding domain (LBD). (B) PPARs
act as obligate heterodimers with another
nuclear hormone receptor called RXR. In
the presence of ligands, co-activator pro-
teins are recruited to supplant co-repres-
sors and transcription is activated. 
(C) Known PPARα ligands, including
fibrates in clinical use (fenofibrate, gemfi-




















response to oleylethanolamide. Additionally, other
PPARα agonists were able to mimic the effects of
oleylethanolamide, even though they exhibit little struc-
tural similarity (Figure 2C). Oleylethanolamide was also
able to elicit ‘traditional’ effects of PPARα agonists,
such as reducing triglyceride and cholesterol levels in
obese rats. Most importantly, the effects of oleyle-
thanolamide on body weight and food intake could not
be elicited in PPARα null mice. Taken together, these
data make a compelling case that oleylethanolamide is
an endogenous ligand of PPARα, and that the appetite
suppressant effects of oleylethanolamide are mediated
by this interaction.
Many important questions remain, however. In
which cells of the intestine is oleylethanolamide
generated? A likely source would be the gut epithe-
lium, the first cells to come into contact with nutri-
ents in the lumen, and which are known to express
PPARα [9]. It is possible, of course, that oleylethan-
olamide acts as a paracrine agent that enters nerve
terminals in the intestinal wall, but then the signal
would have to be transported in retrograde fashion
for the length of the vagus nerve to the cell bodies in
the nodose ganglia near the brainstem in order to
reach PPARα in the cell nucleus. What are the
targets of oleylethanolamide in the periphery that
mediate the appetite suppressant effects? Fu et al.
[7] suggest the nitric oxide synthetase iNOS as one
possible target, and while this remains speculative,
nitric oxide is known to modulate vagal nerve activ-
ity [13,14]. Which nutrients induce oleylethanolamide
formation, and through what mechanism? Is oleyle-
thanolamide the only high-affinity endogenous ligand
for PPARα, or are there other ligands in other tissues
or physiological contexts? Can novel synthetic
PPARα ligands be developed that exert clinically sig-
nificant appetite suppression? 
Providing answers to these questions will keep
researchers busy for a while, but ultimately the
discovery of oleylethanolamide as a bona fide PPAR
ligand is sure to spur the already intense race to
discover other endogenous PPAR ligands. PPARγ in
particular has been shown to have potent antidiabetic
effects, and synthetic ligands are marketed for just that
purpose. PPARγ also has anti-neoplastic and anti-
inflammatory effects [15], and the discovery of novel
chemicals that mediate these processes in vivo would
be of enormous basic and therapeutic interest. 
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